FTXHvsRSPHETF Comparison
VS
First Trust Nasdaq Pharmaceuticals ETF (FTXH) and Invesco S&P 500® Equal Weight Health Care ETF (RSPH) belong to the same industry segment: US Health Care. FTXH's top 1 sector exposures are Healthcare. In contrast, RSPH's top sector exposures are Healthcare and Consumer Non-Cyclicals. FTXH is more expensive with a Total Expense Ratio (TER) of 0.6%, versus 0.4% for RSPH. FTXH is up 23.32% year-to-date (YTD) with +$978M in YTD flows. RSPH performs worse with 13.31% YTD performance, and -$2M in YTD flows. Run a side-by-side ETF comparison of FTXH and RSPH below, and assess how they stack up in performance, liquidity, risk, exposure, holdings, and more, helping you select the best ETF for your investments.
Find out how industry players manage ETF portfolios. Discover our library of Model portfolios
FTXH vs RSPH performance and flow charts
Performance
Cumulative Flows
Historic performance and flows
Data as of 09/10/2026
| 1M | 3M | YTD | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|---|---|
| Perf. | FTXH RSPH | +0.75%-0.16% | +14.81%+12.90% | +23.32%+13.31% | +46.70%+24.71% | +58.20%+29.20% | +66.91%+18.61% |
| Flows | FTXH RSPH | +$41M+$42M | +$968M+$89M | +$978M-$2M | +$981M-$22M | +$973M-$316M | +$977M-$272M |
Volatility and drawdown
| 3M | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|
| Volatility | FTXH RSPH | +20.07%+20.83% | +17.74%+16.91% | +16.99%+15.88% | +16.34%+16.79% |
| Max drawdown | FTXH RSPH | -5.34%-5.57% | -7.50%-10.87% | -19.32%-16.96% | -19.32%-21.91% |
| Max drawdown duration | FTXH RSPH | 16d22d | 99d116d | 393d434d | 393d817d |
Trading data
FTXH | RSPH | |
Last sale 9/11/2026 at 1:30 PM | $40.47 | $36.08 |
| Previous close 09/10/2026 | $40.52 | $35.92 |
| Consolidated volume 09/10/2026 | ||
| Average volume 30 days | ||
| Average discount or premium 30 days | ||
| Average Bid/Ask spread 30 days |
Replication quality
Data as of August 31, 2026
1-year trailing difference
Create an account to view replication metrics
Join for free
FTXH | RSPH | |
|---|---|---|
| Tracking error | ||
| Tracking difference | ||
| 1 year cumulative return difference | ||
| Best | ||
| Worst | ||
| Daily return difference | ||
| Average | ||
| Worst | ||
Advertisement
Main metrics
Last update 9/11/2026 at 1:30 PM
Live
Closed
FTXH | RSPH | |
|---|---|---|
| Last price | $40.47 | $36.08 |
| 1D performance | -0.13% | +0.45% |
| AuM | $1.04 B | $831.15 M |
| E/R | 0.6% | 0.4% |
Characteristics
FTXH | RSPH | |
|---|---|---|
| Management strategy | Passive | Passive |
| Provider | First Trust | Invesco |
| Benchmark | NASDAQ US Smart Pharmaceuticals Index | S&P 500 Equal Weight Health Care Index |
| N° of holdings | 49 | 59 |
| Asset class | Equities | Equities |
| Trailing 12m distribution yield | Join | Join |
| Inception date | September 20, 2016 | November 1, 2006 |
| ESG | No | No |
Advertisement
Exposure
Countries
FTXH
USA
95.79%
Other
4.21%
RSPH
USA
96.6%
Other
3.4%
Sectors
FTXH
Healthcare
99.86%
Other
0.14%
RSPH
Healthcare
98.34%
Other
1.66%
Advertisement
Diversification
FTXH
Total weight of top 15 holdings out of 15
66.98%
RSPH
Total weight of top 15 holdings out of 15
28.14%
Top 15 holdings
Data as of July 31, 2026
FTXH
Merck & Co., Inc.
7.58%
Eli Lilly & Co.
7.43%
AbbVie, Inc.
7.11%
Johnson & Johnson
6.78%
Bristol Myers Squibb Co.
6.61%
Amgen, Inc.
3.53%
Biogen, Inc.
3.52%
Vertex Pharmaceuticals, Inc.
3.43%
Viatris, Inc.
3.40%
Regeneron Pharmaceuticals, Inc.
3.34%
Pfizer Inc.
3.17%
Cardinal Health, Inc.
3.14%
Gilead Sciences, Inc.
3.03%
Incyte Corp.
2.48%
United Therapeutics Corp.
2.43%
RSPH
Bio-Techne Corp.
2.10%
IQVIA Holdings, Inc.
2.08%
Veeva Systems, Inc.
1.95%
Charles River Laboratories International, Inc.
1.93%
Mettler-Toledo International, Inc.
1.89%
Baxter International, Inc.
1.87%
DaVita, Inc.
1.86%
Abbott Laboratories
1.86%
Incyte Corp.
1.85%
Thermo Fisher Scientific, Inc.
1.83%
Moderna, Inc.
1.82%
AbbVie, Inc.
1.79%
Universal Health Services, Inc.
1.78%
Regeneron Pharmaceuticals, Inc.
1.77%
Quest Diagnostics, Inc.
1.77%
Frequently asked questions about FTXH and RSPH
How have the FTXH and RSPH ETFs performed in 2026?
As of September 10, 2026, FTXH is up 23.32% year-to-date (YTD), while RSPH has returned 13.31%. That puts FTXH better performer ahead so far this year.
Which ETF is attracting more investor money: FTXH or RSPH?
Year-to-date, the FTXH ETF saw +$978M in flows, compared to -$2M for RSPH.
Which ETF is more volatile: FTXH or RSPH?
Over the past year, FTXH had a volatility of 17.74%, while RSPH experienced 16.91%.
Which ETF is bigger: FTXH or RSPH?
As of September 10, 2026, FTXH holds $1.04 B in assets under management (AUM), while RSPH manages $831.15 M.
What sectors do the FTXH and RSPH ETFs invest in?
FTXH leans toward sectors like Healthcare. Meanwhile, RSPH focuses on Healthcare.
What are the top holdings of the FTXH ETF and RSPH ETF?
FTXH top holdings include Merck & Co., Inc., Eli Lilly & Co. and AbbVie, Inc.. RSPH holds in its top three: Bio-Techne Corp., IQVIA Holdings, Inc. and Veeva Systems, Inc..
Which ETF is more diversified: FTXH or RSPH?
FTXH holds 49 securities with 66.98% of its assets in the top 15. RSPH has 59 securities and a top 15 weight of 28.14%.
Advertisement
Latest news about FTXH & RSPH
Advertisement
